Fundamentals-based quality & risk · not a recommendation
Tatva Chintan Pharma Chem Ltd scores 39/100 (Caution) on the Orion Score — weak business quality (42), poor growth (10), strong balance-sheet safety (77) and rich valuation (20). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
42/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹134.14 | ₹10.32 | 13.7% | ₹4.41 |
| Q3 2026 | ₹131.33 | ₹15.16 | 12.5% | ₹6.49 |
| Q2 2026 | ₹123.52 | ₹9.92 | 10.7% | ₹4.24 |
| Q1 2026 | ₹116.86 | ₹6.65 | 7.2% | ₹2.84 |
| Q4 2025 | ₹107.86 | ₹1.03 | 1.6% | ₹0.44 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2026 | ₹505.86 | ₹42.05 | ₹96.71 | 11.1% |
| FY 2025 | ₹382.71 | ₹5.71 | ₹36.53 | 1.7% |
| FY 2024 | ₹390.5 | ₹30.35 | ₹75.32 | 11.3% |
| FY 2023 | ₹420.89 | ₹45.49 | ₹62.33 | 13.9% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| TATVA ★ | ₹2,768 Cr | 65.79 | 7.12% | 5.53% | 0.15x | 13.70% |
| AETHER | ₹19,918 Cr | 90.08 | 11.68% | 9.38% | 0.19x | 21.06% |
| ATUL | ₹18,360 Cr | 27.11 | 10.56% | 11.53% | 0.03x | 12.07% |
| CHAMBLFERT | ₹18,180 Cr | 9.31 | 19.66% | 20.45% | 0.10x | 5.92% |
| ANURAS | ₹14,436 Cr | 82.66 | 8.65% | 5.76% | 0.41x | 18.15% |
| ACI | ₹6,512 Cr | 60.98 | 6.58% | 5.55% | 0.24x | 6.94% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹836.25 | ₹818.72 | ₹758.86 | ₹658.05 |
| Equity | ₹738.82 | ₹737.08 | ₹514.79 | ₹473.09 |
| Total Debt | ₹36.39 | ₹14.27 | ₹170.26 | ₹119.94 |
| Cash | ₹11.37 | ₹35.3 | ₹27.36 | ₹63.02 |
| Net Debt | ₹25.01 | — | ₹142.89 | ₹56.92 |
| Working Capital | ₹169.22 | ₹218.24 | ₹73.56 | ₹264.44 |
Q3 FY2026
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q3 FY2026 | 72.02% | 4.17% ↑ | 3.32% ↓ | 20.49% ↓ |
| Q2 FY2026 | 72.02% | 3.4% ↑ | 3.87% ↓ | 20.72% ↑ |
| Q1 FY2026 | 72.02% | 3.26% ↓ | 5.11% ↓ | 19.6% ↑ |
| Q4 FY2025 | 72.02% | 3.3% ↓ | 5.46% ↓ | 19.21% ↑ |
| Q3 FY2025 | 72.02% | 3.36% ↑ | 6.34% ↓ | 18.27% ↑ |
| Q2 FY2025 | 72.02% | 3.33% ↓ | 6.83% ↓ | 17.81% ↑ |
| Q1 FY2025 | 72.02% | 3.37% ↓ | 10.64% ↓ | 13.97% ↑ |
| Q4 FY2024 | 72.02% | 3.65% | 12.84% | 11.49% |
No recent corporate actions
5 mutual fund schemes
Ask: "Is Tatva Chintan Pharma Chem Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Tatva Chintan Pharma Chem Ltd is listed on the NSE under the Chemicals sector, Specialty Chemicals industry. ISIN: INE0GK401011. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.